Clinical Trial Update: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Onapristone and Anastrozole for refractory hormone receptor-positive endometrial cancer; the trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Clear Cell Carcinoma
• Endometrial Endometrioid Adenocarcinoma
• Endometrial Mixed Cell Adenocarcinoma
• Endometrial Serous Carcinoma
• Endometrial Undifferentiated Carcinoma

Drugs mentioned

• ARIMIDEX (anastrozole)
• Onapristone (onapristone)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING